MINI REVIEW article
Front. Cardiovasc. Med.
Sec. Cardio-Oncology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1614878
This article is part of the Research TopicmiRNA Interference: New Frontiers in Heart Failure TherapyView all articles
MicroRNAs in Anthracycline Cardiotoxicity: Biomarkers, Mechanisms, and Therapeutic Advances
Provisionally accepted
- 1Nanjing University of Chinese Medicine, Nanjing, China
- 2China Pharmaceutical University, Nanjing, Jiangsu Province, China
- 3Kunshan Traditional Chinese Medicine Hospital, Kunshan, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Anthracycline-based chemotherapy remains one of the most effective cancer treatments but is often limited by dose-dependent cardiotoxicity, which poses a significant clinical chal-lenge. Traditional monitoring methods, relying on non-specific biomarkers and cardiac im-aging, typically delay diagnosis until irreversible damage has already occurred. Recent studies have highlighted microRNAs (miRNAs)-small, non-coding RNA molecules with tissue specificity-as promising biomarkers for the early detection and therapeutic targets of anthracycline-induced cardiotoxicity. This review summarizes current findings on miRNA modulation in cardiac tissue and circulation during anthracycline treatment, explores their roles in the mechanisms of cardiac injury, and examines their potential for prevention and therapy. A deeper understanding of miRNA regulation offers substantial prospects for im-proving the management of chemotherapy-induced cardiac dysfunction.
Keywords: Anthracycline, cardiotoxicity, MicroRNAs, biomarker, mechanisms
Received: 23 Apr 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Mao, Hu, Yu, Xie, Chang, Peng and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Cheng Chang, Kunshan Traditional Chinese Medicine Hospital, Kunshan, 215300, Jiangsu Province, China
Juanjuan Peng, Nanjing University of Chinese Medicine, Nanjing, China
Yang Zhang, Nanjing University of Chinese Medicine, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.